Eneida R. Nemecek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eneida R. Nemecek has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Amrita Desai
Center for Hematological Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
2 shared publications- Andrew C. Harris
MSK Kids Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications Denise Lackey
Center for Hematological Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
2 shared publications- Henrique Bittencourt
Department of Pediatrics, Hematology-Oncology Division, CHU Sainte-Justine, Montreal, QC, Canada
2 shared publications - Jeffery J. Auletta
NMDP, Minneapolis, MN
2 shared publications - Jessica Leonard
Oregon Health Sciences, Portland, Oregon, United States
2 shared publications
Latest Publications
- 1 July 2026
- Published by Elsevier in Blood Reviews
- Vol. 77, 101417
What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy
- 1 July 2026
- Published by Elsevier in Blood Reviews
- Vol. 77, 101417
What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy
- Open Access
- 1 October 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 84.e1-84.e16
Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort
- 1 October 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 84.e1-84.e16
Open AccessIdentification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort
- 27 September 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (2) , e120-e125
Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma
- 27 September 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (2) , e120-e125
Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 2405
Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon
Disclosures. Chen:Fate: Research Funding; Intellia: Consultancy; Kite: Consultancy, Research Funding; Elsevier: Consultancy; Novartis: Research Funding. Leonard
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 2405
Open AccessAccess to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon
Disclosures. Chen:Fate: Research Funding; Intellia: Consultancy; Kite: Consultancy, Research Funding; Elsevier: Consultancy; Novartis: Research Funding. Leonard
- 14 January 2021
- Published by Springer Nature
- p. 531-541
Gastrointestinal Complications
- Open Access
- 1 August 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (8) , 1651-1656
Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium
- 1 August 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (8) , 1651-1656
Open AccessTreosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium
- 17 July 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (539)
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
Dasatinib or TNK2-specific inhibitors may treat PTPN11-mutant leukemia.
- 17 July 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (539)
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
Dasatinib or TNK2-specific inhibitors may treat PTPN11-mutant leukemia.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10523
Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).
10523 Background: The global ELIANA trial (NCT02435849) evaluates the efficacy and safety of CTL019, a single infusion of genetically modified autologous chimeric antigen receptor–expressing T cells targeting CD19+ cells in pediatric and young adult r/r B-ALL pts. Analyses show a complete response rate of 82% with or without complete blood count recovery ≤ 3 months. A serious adverse event rate of 71% was observed in ≤ 8 weeks of infusion, decreasing to 17% at > 8 weeks (Grupp S, et al. Blood. 2016;128(22) [abstract 221].). This analysis further evaluates the clinical benefit of CTL019. QOL was assessed before and after CTL019 infusion. Methods: Infused pts were 3-23 y/o with CD19+ B-ALL who were chemo refractory, relapsed after allogeneic stem cell transplant (SCT), or otherwise ineligible for SCT. Pts ≥ 8 y completed the Pediatric Quality of Life Inventory (PedsQL) and EuroQol EQ-5D at baseline and following CTL019 infusion. Minimal clinically important differences are estimated to be 4.4 and 7 to 10 for PedsQL and EQ-5D, respectively. Results: 62 of 81 enrolled pts were infused; 56% had relapsed after SCT with median of 3 prior therapies. At interim analysis, 50 pts were treated ≥ 3 months prior to data cutoff and eligible for primary efficacy analysis. A total of 39 pts were ≥ 8 y. Mean PedsQL total and EQ-5D VAS scores, respectively, were 58.4 and 69.4 at baseline. Mean changes from baseline for the PedsQL total and EQ VAS scores, respectively, were 13.9 and 13.7 at month 3 and 12.8 and 10.9 at month 6, supporting clinically meaningful improvements in QOL. Similar trends were observed with each PedsQL subscale. With EQ-5D, the proportions of pts reporting problems with mobility, self-care, usual activities, anxiety/depression, or pain/discomfort were notably decreased at months 3 and 6 compared with baseline. Conclusions: Clinically meaningful improvements in QOL were observed at 3 and 6 months after CTL019 therapy in pediatric and young adult r/r B-ALL pts, including fewer problems in each EQ-5D domain. These results suggest improved QOL after this one-time immunocellular therapy beyond the period of acute toxicities. Clinical trial information: NCT02435849.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10523
Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).
10523 Background: The global ELIANA trial (NCT02435849) evaluates the efficacy and safety of CTL019, a single infusion of genetically modified autologous chimeric antigen receptor–expressing T cells targeting CD19+ cells in pediatric and young adult r/r B-ALL pts. Analyses show a complete response rate of 82% with or without complete blood count recovery ≤ 3 months. A serious adverse event rate of 71% was observed in ≤ 8 weeks of infusion, decreasing to 17% at > 8 weeks (Grupp S, et al. Blood. 2016;128(22) [abstract 221].). This analysis further evaluates the clinical benefit of CTL019. QOL was assessed before and after CTL019 infusion. Methods: Infused pts were 3-23 y/o with CD19+ B-ALL who were chemo refractory, relapsed after allogeneic stem cell transplant (SCT), or otherwise ineligible for SCT. Pts ≥ 8 y completed the Pediatric Quality of Life Inventory (PedsQL) and EuroQol EQ-5D at baseline and following CTL019 infusion. Minimal clinically important differences are estimated to be 4.4 and 7 to 10 for PedsQL and EQ-5D, respectively. Results: 62 of 81 enrolled pts were infused; 56% had relapsed after SCT with median of 3 prior therapies. At interim analysis, 50 pts were treated ≥ 3 months prior to data cutoff and eligible for primary efficacy analysis. A total of 39 pts were ≥ 8 y. Mean PedsQL total and EQ-5D VAS scores, respectively, were 58.4 and 69.4 at baseline. Mean changes from baseline for the PedsQL total and EQ VAS scores, respectively, were 13.9 and 13.7 at month 3 and 12.8 and 10.9 at month 6, supporting clinically meaningful improvements in QOL. Similar trends were observed with each PedsQL subscale. With EQ-5D, the proportions of pts reporting problems with mobility, self-care, usual activities, anxiety/depression, or pain/discomfort were notably decreased at months 3 and 6 compared with baseline. Conclusions: Clinically meaningful improvements in QOL were observed at 3 and 6 months after CTL019 therapy in pediatric and young adult r/r B-ALL pts, including fewer problems in each EQ-5D domain. These results suggest improved QOL after this one-time immunocellular therapy beyond the period of acute toxicities. Clinical trial information: NCT02435849.
- 21 April 2015
- Published by Springer Nature
- p. 267-275
Gastrointestinal Complications